Log In
BCIQ
Print this Print this
 

BeiGene-283, BGB-283

  Manage Alerts
Collapse Summary General Information
Company BeiGene Ltd.
DescriptionSecond-generation small molecule BRAF inhibitor
Molecular Target BRAF
Mechanism of ActionBRAF inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$233.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/03/2013

Undisclosed

Undisclosed

$233.0M

Get a free BioCentury trial today